|
Jul 11
|
Untapped Patient Base, Ingrezza Growth Keep Neurocrine (NBIX) on Guggenheim’s Buy List
|
|
Jul 10
|
Acadia Emerges From Behind The Scenes With A Potential $12 Billion Opportunity
|
|
Jul 9
|
Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2025 Financial Results
|
|
Jun 30
|
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-01435, a Long-Acting Corticotropin-Releasing Factor Type 1 Receptor Antagonist
|
|
Jun 27
|
Neurocrine Biosciences Presents New Post-Hoc Data Analyses from KINECT®-HD Study Demonstrating Significant Reduction in Disease Burden with INGREZZA® (valbenazine) Capsules for Huntington's Disease Chorea
|
|
Jun 23
|
CPRX vs. NBIX: Which Stock Is the Better Value Option?
|
|
Jun 20
|
Neurocrine Biosciences Presents New Data Showing Significant Patient-Reported Improvements in Health-Related Quality of Life with INGREZZA® (valbenazine) Capsules in Older Adults with Tardive Dyskinesia
|
|
Jun 9
|
Neurocrine Biosciences Appoints Lewis Choi as Chief Information Officer
|
|
May 28
|
Neurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025
|
|
May 22
|
Exploring 3 High Growth Tech Stocks In The US Market
|
|
Apr 14
|
Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2025 Financial Results
|
|
Apr 7
|
Implied Volatility Surging for Neurocrine Biosciences (NBIX) Stock Options
|
|
Apr 4
|
Neurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medical Officer
|
|
Mar 14
|
Big Pharma Walked Away From Mental Health. Why Some Are Coming Back.
|
|
Mar 11
|
Neurocrine Biosciences to Present at the Stifel 2025 Virtual CNS Forum
|
|
Feb 24
|
High Growth Tech Stocks To Watch In February 2025
|
|
Feb 21
|
Is Neurocrine Biosciences (NBIX) One of the Best Fast Growth Stock to Buy Right Now?
|
|
Feb 21
|
Neurocrine Biosciences' (NASDAQ:NBIX) Performance Is Even Better Than Its Earnings Suggest
|
|
Feb 21
|
Neurocrine Biosciences Board of Directors Authorizes $500 Million Share Repurchase Program
|
|
Feb 18
|
Neurocrine (NBIX): Among Top Insider Stock Buys And Sells In January
|